Source and publication year

Year of Study

Study Design

No. of patients

No. of neuropathic incidence

Ribas A. et al.

2015

randomized phase 2 trial

N = 178 (pembrolizumab 2 mg/kg)

N = 179 (pembrolizumab 10 mg/kg)

N = 2

N = 1

James et al.

2017

Review

N = 3763 (nivolumab with or without ipilimumab)

N = 22

Tomohiro et al.

2017

randomized controlled trials-metanalysis

N = 3450 (single-agent PD-1/PD-L1 inhibitor or chemotherapy)

N = 6

Paolo et. al

2017

randomized, double-blind, multicenter, phase 3 study

N = 364 (ipilimumab 10 mg/kg or 3 mg/kg)

N = 3

Antonia et al.

2016

Multicenter, open-label, two-stage, multi-arm phase 1/2 trial.

N = 54 (nivolumab 3 mg/kg plus ipilimumab 1 mg/kg)

N = 1

Weber JS et. al

2015

randomized, open-label, phase 2 study,

N = 68 (Nivolumab followed by ipilimumab)

N = 1